Lung cancer drug cocktail trial ends early – what we know
NCT ID NCT04619433
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tested a combination of three drugs—camrelizumab (an immunotherapy), famitinib (a targeted therapy), and standard chemotherapy—in 48 people with advanced non-squamous non-small-cell lung cancer that did not have certain genetic changes. The study aimed to see if the combo worked better than chemo alone, but it was terminated early, so we have limited information on its effectiveness or safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Camrelizumab (an immunotherapy drug), Famitinib (a targeted therapy), and chemotherapy (pemetrexed and carboplatin)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with a common type of lung cancer that lacks certain genetic mutations.
- What could go wrong
- The trial was terminated early with only 48 participants, so results are limited. It is unclear if the combination is safe or effective, and side effects from multiple drugs can be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hosipital
Beijing, Beijing Municipality, 100089, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Hubei Cancer Hospita
Wuhan, Hubei, 430079, China
-
Shanghai Lung Hospital
Shanghai, Shanghai Municipality, 200433, China
-
Shengjing Hospita of China Medical University
Shenyang, Liaoning, 110022, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
West China Hospital，Sichuan University
Chengdu, Sichuan, 610000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a novel drug combo outperform standard chemo for lung cancer?
- Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?
- New lung cancer drug aims to match Keytruda's success
- Targeted drug shows promise for Gene-Driven lung cancers
- Engineered virus plus immunotherapy aims to outperform chemo in advanced lung cancer
- New drug duo aims to tackle Hard-to-Treat cancers